keine Finanzberatung

CRL · Charles River Labs

Preclinical CRO: safety testing and lab models for drug developers

Risiko 6/10 · MODERATE-HIGH RISK · cyclical CRO recovery bet · $288.50 ▼ 1.65%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $288.50
  • Market cap $13.9B
  • P/E (ttm) n/a
  • Div yield none
  • 52-wk range $144.26 – $303.31
  • Index rank #480 / —

Wichtigste Risiken

  • FDA phase-out of animal-testing requirements (Shareholders) — HIGH
  • Biotech funding drought starving preclinical demand (Shareholders) — MED
  • Rally already prices a recovery revenue hasn't shown (Shareholders) — MED
  • Insiders selling heavily into the strength (Shareholders) — MED

Fazit

The upgrades and the chart say turnaround, but revenue still shrinks and the regulator is questioning the product; this is a momentum trade, not a compounding hold.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.